Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron ODF plus Huoxiang Zhengqi to prevent delayed CINV after highly emetogenic chemotherapy
ChiCTR2500106531Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ondansetron and Huoxiang Zhengqi in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Response rate of chemotherapy-induced nausea and vomiting in the delayed period (25–120 hours). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ondansetronHuoxiang Zhengqi
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500106531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106531.